<p><meta name="uuid" content="uuidRjlcNc0Qy0rI" /></p>

<p>The connection between a poor diet or poorly controlled metabolic conditions such as diabetes and higher cancer risk is partly elucidated by a previously unidentified mechanism that deactivates genes inhibiting tumour formation.</p>

<p>Using mouse models, human tissue, and in vitro-produced human breast organoids, researchers from Singapore and the UK discovered that disruptions in glucose metabolism may promote the growth of cancer by momentarily blocking the BRCA2 gene, which guards against tumours.</p>

<p>Cancer pharmacologist Li Ren Kong of the Cancer Science Institute of Singapore (CSI Singapore), who is the study's primary author, states that "these findings raise awareness of the impact of diet and weight control in the management of cancer risks."</p>

<p>"We started the study aiming to understand what factors elevate risk in families susceptible to cancer, but ended up discovering a deeper mechanism linking an essential energy consumption pathway to cancer development," he added.</p>

<p>The study also calls into question a long-standing idea concerning cancer-protective genes. Recent research has discovered that a mutation in one of a cell's two BRCA2 genes is associated with a variety of cancers. Interestingly, mice and human cells with this mutation do not exhibit the typical symptoms of genetic instability observed in cells with both copies of the&nbsp;gene altered.</p>

<p><strong>Also read:&nbsp;<a href="http://wionews.com/science/accelerated-aging-heightens-cancer-risk-in-younger-population-study-709980" target="_blank">Accelerated ageing is heightening cancer risk in younger population: Study</a></strong></p>

<p>In mice, having only one copy of BRCA2 impacted does not appear to create significant difficulties with organ development or DNA repair in most tissues. However, cells with this mutation tend to be more prone to stress, such as exposure to environmental pollutants like formaldehyde or acetaldehyde, which can lower BRCA2 protein levels and cause functional issues.</p>

<h2><strong>How do disruptions in glucose metabolism affect BRCA2 function?</strong></h2>

<p>The researchers initially looked at persons who had inherited one defective copy of BRCA2. They discovered that these people's cells were more susceptible to methylglyoxal (MGO), which is created when cells break down glucose for energy during glycolysis.</p>

<p>The researchers observed that MGO can temporarily block the BRCA2 protein's tumor-suppressing capabilities, causing mutations associated with cancer development.&nbsp;</p>

<p>Overall, their findings imply that alterations in glucose metabolism can affect BRCA2 function via MGO, leading to cancer genesis and progression. This new knowledge may help to develop cancer prevention or early detection measures.</p>


The connection between a poor diet or poorly controlled metabolic conditions such as diabetes and higher cancer risk is partly elucidated by a previously unidentified mechanism that deactivates genes inhibiting tumour formation.

The connection between a poor diet or poorly controlled metabolic conditions such as diabetes and higher cancer risk is partly elucidated by a previously unidentified mechanism that deactivates genes inhibiting tumour formation. Using mouse models, human tissue, and in vitro-produced human breast organoids, researchers from Singapore and the UK discovered that disruptions in glucose metabolism may promote the growth of cancer by momentarily blocking the BRCA2 gene, which guards against tumours. Cancer pharmacologist Li Ren Kong of the Cancer Science Institute of Singapore (CSI Singapore), who is the study's primary author, states that "these findings raise awareness of the impact of diet and weight control in the management of cancer risks." "We started the study aiming to understand what factors elevate risk in families susceptible to cancer, but ended up discovering a deeper mechanism linking an essential energy consumption pathway to cancer development," he added. The study also calls into question a long-standing idea concerning cancer-protective genes. Recent research has discovered that a mutation in one of a cell's two BRCA2 genes is associated with a variety of cancers. Interestingly, mice and human cells with this mutation do not exhibit the typical symptoms of genetic instability observed in cells with both copies of the gene altered. Also read: Accelerated ageing is heightening cancer risk in younger population: Study In mice, having only one copy of BRCA2 impacted does not appear to create significant difficulties with organ development or DNA repair in most tissues. However, cells with this mutation tend to be more prone to stress, such as exposure to environmental pollutants like formaldehyde or acetaldehyde, which can lower BRCA2 protein levels and cause functional issues. How do disruptions in glucose metabolism affect BRCA2 function? The researchers initially looked at persons who had inherited one defective copy of BRCA2. They discovered that these people's cells were more susceptible to methylglyoxal (MGO), which is created when cells break down glucose for energy during glycolysis. The researchers observed that MGO can temporarily block the BRCA2 protein's tumor-suppressing capabilities, causing mutations associated with cancer development. Overall, their findings imply that alterations in glucose metabolism can affect BRCA2 function via MGO, leading to cancer genesis and progression. This new knowledge may help to develop cancer prevention or early detection measures.

Study uncovers mechanism linking diet, diabetes, and cancer risk

<p>A few months ago, India’s drug regulator Central Drugs Standard Control Organisation (CDSCO), approved the commercial use of CAR-T cell therapy. The therapy includes genetically reprogramming a patient’s immune system to fight cancer.</p>

<p>Today, the therapy has turned out to be a lifesaver for many patients, including for Dr (Col) V K Gupta, a Delhi-based gastroenterologist with 28 years of experience of working in the Indian Army, Indian Express reported.</p>

<p>He accessed the therapy by paying just INR 42 lakh or $50,000, whereas a similar therapy costs up to INR 4 crore $480,000 abroad.</p>

<p>Doctors at the Tata Memorial Hospital, where Gupta underwent the procedure, said he is “currently free of cancer cells.” Gupta is the first patient to have achieved this status, something he could only dream of just a year ago.</p>

<p>The doctor who performed the therapy on Gupta said he was totally free of cancer cells.&nbsp; “While it’s premature to claim a lifelong cure, the patient is currently free of cancer cells,” Dr Hasmukh Jain, hemato-oncologist and associate professor at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, was quoted as saying by the Indian Express.</p>

<h2><strong>Still premature to tell success rate</strong></h2>

<p>However, the doctor added that it was still premature to tell about the success rate of the therapy. He said the initial findings suggest “better survival chances and lower remission rates” for patients in the early stages of cancer.</p>

<p><strong>Watch:&nbsp;UK's King Charles diagnosed with cancer, continue with royal engagements</strong></p>

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/uks-king-charles-diagnosed-with-cancer-continue-with-royal-engagements-687559/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

<p>“Years of data are needed to identify potential relapse timelines for patients, if any are ever reported among these patients,” Jain said.</p>

<h2><strong>The therapy</strong></h2>

<p>The therapy, NexCAR19, is developed by ImmunoACT, a company incubated at the Indian Institute of Technology Bombay (IITB), IIT-B and Tata Memorial Hospital. It focuses on treating B-cell cancers (types of cancers that form in the immune system’s cells) such as leukaemia and lymphoma.</p>

<p><strong>Also read:&nbsp;<a data-jsarwt="1" data-usg="AOvVaw11oIzPs9ILB8xoI1Xjhz6L" data-ved="2ahUKEwi7peiLjpmEAxVkxjgGHX4CCWsQxfQBKAB6BAgNEAE" href="https://www.wionews.com/entertainment/lifestyle/news-king-charles-cancer-diagnosis-expert-insights-on-timely-cancer-screening-and-treatment-687531" jsname="YKoRaf">King Charles’ cancer diagnosis: Expert insights on timely cancer screening and treatment</a>read:&nbsp;</strong></p>

<p>The CDSCO approved its commercial use in October 2023. Today, the therapy is available in over 30 hospitals in more than 10 cities in India. Patients aged above 15, who are suffering from B-cell cancers are eligible for the treatment.</p>

<p><em>(With inputs from agencies)</em></p>


A few months ago, India’s drug regulator Central Drugs Standard Control Organisation (CDSCO), approved the commercial use of CAR-T cell therapy. The therapy includes genetically reprogramming a patient’s immune system to fight cancer.

A few months ago, India’s drug regulator Central Drugs Standard Control Organisation (CDSCO), approved the commercial use of CAR-T cell therapy. The therapy includes genetically reprogramming a patient’s immune system to fight cancer. Today, the therapy has turned out to be a lifesaver for many patients, including for Dr (Col) V K Gupta, a Delhi-based gastroenterologist with 28 years of experience of working in the Indian Army, Indian Express reported. He accessed the therapy by paying just INR 42 lakh or $50,000, whereas a similar therapy costs up to INR 4 crore $480,000 abroad. Doctors at the Tata Memorial Hospital, where Gupta underwent the procedure, said he is “currently free of cancer cells.” Gupta is the first patient to have achieved this status, something he could only dream of just a year ago. The doctor who performed the therapy on Gupta said he was totally free of cancer cells. “While it’s premature to claim a lifelong cure, the patient is currently free of cancer cells,” Dr Hasmukh Jain, hemato-oncologist and associate professor at the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, was quoted as saying by the Indian Express. Still premature to tell success rate However, the doctor added that it was still premature to tell about the success rate of the therapy. He said the initial findings suggest “better survival chances and lower remission rates” for patients in the early stages of cancer. Watch: UK's King Charles diagnosed with cancer, continue with royal engagements × “Years of data are needed to identify potential relapse timelines for patients, if any are ever reported among these patients,” Jain said. The therapy The therapy, NexCAR19, is developed by ImmunoACT, a company incubated at the Indian Institute of Technology Bombay (IITB), IIT-B and Tata Memorial Hospital. It focuses on treating B-cell cancers (types of cancers that form in the immune system’s cells) such as leukaemia and lymphoma. Also read: King Charles’ cancer diagnosis: Expert insights on timely cancer screening and treatmentread: The CDSCO approved its commercial use in October 2023. Today, the therapy is available in over 30 hospitals in more than 10 cities in India. Patients aged above 15, who are suffering from B-cell cancers are eligible for the treatment. (With inputs from agencies)

India: First patient declared ‘cancer-free’ using indigenous CAR-T cell therapy

Mumbai-based Epigeneres Biotech Private Ltd, in collaboration with Singapore-based Tzar Labs, claims to have developed the world’s first pan-cancer imminent-detection blood test. According to Tzar Labs' Ashish Tripathi, the test can detect mutations and dysfunction pathways from a blood sample much before a tumor forms, enabling early detection and significantly improving survival rates. The technology has undergone a 1,000-patient study in India and clinical trials with the NHS have commenced. The test has already been launched in India, with further expansion plans underway. What are the key claims made by Tzar Labs regarding their blood test for cancer detection and how does early detection impact the prognosis and treatment of cancer patients? Watch Vikram Chandra in a special conversation with Ashish Tripathi

Hope on Horizon for cancer patients?

Are you sleeping less than 7.5 hours a night? Your life could be at risk. Studies show sleep deprivation increases the risk of cancer. Sleeping less also makes you a bad worker and takes a toll on your pocket.

Gravitas Plus: Do you sleep for less than 7.5 hours? Watch this

cancer-news

Cancer News, News on Cancer News, stories on Cancer News, articles on Cancer News, Cancer News stories at Wion, Cancer News news, Cancer News latest news

cancer news

Study uncovers mechanism linking diet, diabetes, and cancer risk

India: First patient declared ‘cancer-free’ using indigenous CAR-T cell therapy

Hope on Horizon for cancer patients?

Gravitas Plus: Do you sleep for less than 7.5 hours? Watch this